26 related articles for article (PubMed ID: 20097563)
1. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information.
Paoletta S; Sabbadin D; von Kügelgen I; Hinz S; Katritch V; Hoffmann K; Abdelrahman A; Straßburger J; Baqi Y; Zhao Q; Stevens RC; Moro S; Müller CE; Jacobson KA
J Comput Aided Mol Des; 2015 Aug; 29(8):737-56. PubMed ID: 26194851
[TBL] [Abstract][Full Text] [Related]
2. Pharmacochemistry of the platelet purinergic receptors.
Jacobson KA; Deflorian F; Mishra S; Costanzi S
Purinergic Signal; 2011 Sep; 7(3):305-24. PubMed ID: 21484092
[TBL] [Abstract][Full Text] [Related]
3. Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2009 Nov; 19(21):6148-56. PubMed ID: 19796941
[TBL] [Abstract][Full Text] [Related]
4. Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2009 Aug; 19(16):4657-63. PubMed ID: 19604694
[TBL] [Abstract][Full Text] [Related]
5. Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
J Med Chem; 2010 Mar; 53(5):2010-37. PubMed ID: 20141147
[TBL] [Abstract][Full Text] [Related]
6. Exploration of a new series of PAR1 antagonists.
Planty B; Pujol C; Lamothe M; Maraval C; Horn C; Le Grand B; Perez M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1735-9. PubMed ID: 20137929
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
8. Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2010 Feb; 20(4):1388-94. PubMed ID: 20097563
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
van Giezen JJ; Humphries RG
Semin Thromb Hemost; 2005 Apr; 31(2):195-204. PubMed ID: 15852223
[TBL] [Abstract][Full Text] [Related]
10. Platelet P2 receptors: old and new targets for antithrombotic drugs.
Cattaneo M
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
[TBL] [Abstract][Full Text] [Related]
11. Platelet ADP receptors and their antagonists.
Benoit P; Dogné JM
Mini Rev Med Chem; 2003 Mar; 3(2):145-8. PubMed ID: 12570847
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic P2Y
Baqi Y; Müller CE
Drug Discov Today; 2019 Jan; 24(1):325-333. PubMed ID: 30291899
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
